A phase 2 trial enrolled 96 patients to study the efficacy of combinational anti-PD-1 (SHR-1210) and anti-VEGFR (Apatinib) in NSCLC patients with wild-type EGFR and ALK (NCT03083041). Here, ALK is linked to non-small cell lung carcinoma.